Lexaria Bioscience Corp. LXRP Archives - Page 25 of 27

ThursdayOct 12, 2017 9:30 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is Frontrunner in the Delivery of Non-Psychoactive Cannabinoids

Lexaria Biosciences Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, has enhanced the ability of cannabinoid-products companies to deliver active ingredients to the body with its patent-protected technology. This technology is already being applied to the use of non-psychoactive cannabinoids, yielding a high-absorption hemp oil formula that is a source of omega and fatty acids, and patents are pending for tetrahydrocannabinol (THC) and other psychoactive cannabinoids along with nicotine and nonsteroidal anti-inflammatory drugs. An article discussing this reads: “The patent awarded to LXRP for the delivery of all non-psychoactive…

TuesdayOct 10, 2017 12:53 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Bioabsorption Tech Boosting Development of CBD Products

Technology improves absorption of cannabidiol and bioactive compounds into the bloodstream It is now being used on all non-psychoactive cannabinoids and applied to edibles and health food products Patents have been awarded in the U.S. and Australia and are pending in 44 countries Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds. Its patent-protected technology has improved the ability of cannabinoid-products companies to deliver active ingredients to the body. With patents pending for tetrahydrocannabinol and other psychoactive cannabinoids (plus nicotine and non-steroidal anti-inflammatory drugs), the current technology…

TuesdayOct 03, 2017 12:39 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Breakthrough Lipid-Based Delivery System Revolutionizes Delivery of Cannabinoids and More

Pioneering biotechnology company Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed a breakthrough lipid-based system that facilitates more efficient delivery of bioactive compounds—not only enhancing bio-absorption and bioavailability but also improving taste, smell and the onset of action. Lexaria intends to out-license this patented and proprietary technology, and the company has already applied this delivery technology to its line of products, which includes ViPova, Lexaria Energy and TurboCBD. An article further discussing this reads: “Lexaria’s novel technology, DehydraTECH™, ticks all these boxes by infusing the molecules of organically sourced hemp oil, high in cannabidiol (CBD), inside the molecules of…

FridaySep 29, 2017 12:53 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Tech Discussed at “Cannabis in the Capital Markets” Event

Clinical studies of TurboCBD™ a topic of discussion at Canadian Securities Exchange-sponsored “Cannabis in the Capital Markets” event Patents cover variety of lipophilic bio-actives, including cannabinoids, nicotine and vitamins Growing portfolio of intellectual property includes 19 patents filed across 44 countries Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), through its proprietary technology for delivering bioactive compounds in lipid formulations, offers licensed partners the ability to include cannabidiol (CBD) in a variety of ingestible products appropriate for medical patients and recreational users alike. In a new report, Grand View Research, Inc., states that the global market for medical cannabis alone is…

MondaySep 25, 2017 1:46 pm

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Technology Targets Many Massive Markets

Technology that improves bio-absorption and bio-availability Bioactive compound delivery system with application across a range of drugs Revenue streams from out-licensing The word in culinary circles is that where there is fat, there is flavor. That’s because fats (there are several different kinds) have a matchless ability to absorb and preserve flavors. Fats belong to a class of compounds called lipids, which the human digestive system absorbs remarkably efficiently. This characteristic makes them ideal for pairing with hard to digest remedials and tonics. Taking a leaf, perhaps, from haute cuisine, this is exactly what Lexaria Bioscience Corp. (CSE: LXX) (OTCQB:…

FridaySep 15, 2017 1:54 pm

QualityStocksNewsBreaks – University of British Columbia to Conduct Clinical Study of Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Game-Changing Oral CBD Product

While cannabidiol and other marijuana-derived substances are traditionally smoked, this can cause damage to the lungs, and edible cannabis products have their drawbacks, too—typically being filled with sugars or other sweeteners to mask the unpleasant flavor associated with cannabis compounds. With its pioneering TurboCBD™ product, however, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral CBD intake, having engineered the product to enhance absorption through the intestinal tract without active compounds being destroyed by stomach acid or broken down by the liver, and this revolutionary product also masks the unpleasant flavor of cannabis compounds. An article further discussing this…

WednesdaySep 13, 2017 3:58 pm

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Oral CBD Product to Be Tested by the University of British Columbia

The University of British Columbia (UBC) will conduct a double-blind study of Lexaria’s TurboCBD™ oral ingestion product TurboCBD™ masks foul tastes, protects pharmaceutical ingredients during stomach passage and increases intestinal absorption by 5-10x The UBC study will include 24 volunteers and test their cognitive and cardiovascular function after single doses and after seven days of administration Traditionally, cannabidiol (CBD) is ingested via inhalation, which can harm the lungs, and many edible products contain unwanted sugars or sweeteners. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral intake with its TurboCBD™ product. Engineered to increase absorption through the intestinal tract,…

ThursdaySep 07, 2017 2:18 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Continues Showcasing Proprietary Research at Cannabis Investment Conferences

Proprietary Lexaria technology improves delivery of bioactive compounds in a variety of products, including cannabis-based gourmet foods Market predictions for the legal marijuana industry forecast $50 billion in sales by 2026 19 patent applications filed and pending in more than 40 countries Following a successful showing at the inaugural Institutional Capital & Cannabis Conference (IC3) in California earlier this month, Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) CEO Chris Bunka expects the company to be noticed by investors. Bunka’s presentation of the company’s latest technology slated to benefit the cannabis industry includes the world’s first clinical study on human volunteers of…

ThursdayAug 31, 2017 3:36 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Begins Laboratory Venture with National Research Council

Collaborative venture could lead to strengthening of company’s patent portfolio, new commercial opportunities Firm receives patent in Australia, anticipates entering that market through cannabinoid licensing arrangements and product distribution partnerships LXRP names Allan Spissinger acting chief financial officer Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has begun laboratory work with the National Research Council ("NRC") (http://dtn.fm/e4oZB). The collaboration will begin studies using LXRP’s patented technologies. The research will include the company’s technology in vitamins, NSAIDs, nicotine and cannabinoids utilizing lipophilic active agents. LXRP has patented technology involving how those agents are ingested into the human body in various edibles, such…

ThursdayAug 31, 2017 9:21 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Clinical Study of High Absorption TurboCBD™ Product

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced the world’s first clinical study on human volunteers of cannabidiol (CBD) within Lexaria’s TurboCBD™ product. The study, which aims to evaluate the effects of TurboCBD™ on both cardiovascular health and cognitive function, will have a double-blind and placebo controlled cross-over design measuring effects after a single dose, as well as seven days of daily dosing, in 24 volunteers. “Lexaria is proud to be advancing our collective knowledge of the benefits of CBD specifically showcasing the benefits of…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP